AbbVie Partners with China’s Zelgen on DLL3-Targeted T-Cell Engager ZG006 in Up-to-$1.2B Deal

Suzhou Zelgen Biopharmaceuticals announced a strategic collaboration and licensing option agreement with AbbVie for ZG006 (Alveltamig), a trispecific T-cell engager targeting DLL3 for small cell lung cancer (SCLC) and other DLL3-expressing cancers.12

AbbVie gains exclusive rights outside Greater China; Zelgen retains 100% rights in Greater China, projected to be 25-30% of global market.1

Deal value up to $1.235 billion in milestones plus high-single to mid-double digit tiered royalties on ex-China net sales.12

ZG006 is in late-stage clinical development with Phase 3 trials planned for Q1 2026 (US) and Q2 2026 (China); has FDA Orphan Drug Designation and China Breakthrough Therapy Designation.1

DLL3 expressed in >80% of SCLC tumors; competes with Amgen's bispecific tarlatamab; fills gap from AbbVie's prior failed DLL3 ADC programs.1

Sources:

1. https://flcube.com/?p=52378

2. https://www.americanpharmaceuticalreview.com/Specialty/Microbiology/1315-News/623467-Zelgen-AbbVie-Sign-Up-to-1-2B-DLL3-T-Cell-Engager-Licensing-Option-Deal/